pharma · Colorectal Cancer · Lymphoma, Extranodal NK-T-Cell
Samsung Bioepis
Samsung Bioepis NL B.V.
Samsung Bioepis trial registry — 25 ClinicalTrials.gov studies with program phase, status, and indication context.
Yeonsu-gu, Incheon 21987, KR HQ
2012 Founded
1,589 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Yeonsu-gu, Incheon 21987, KR
- Founded
- 2012
- Employees
- 1,589
- Programs
- 24
- Drugs
- 34
- Patents
- 0
Samsung Bioepis clinical trials
Registry index of 25 ClinicalTrials.gov studies linked to Samsung Bioepis programs — each row shows trial ID, program name, phase, status, and indication.
Samsung Bioepis trial registry — 25 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Samsung Bioepis.
-
SB27-3004 — Phase 3
Clinical update -
SB27-1005 — Phase 1
Clinical update -
E303-1001 — Phase 1
Clinical update -
SSRI treated group — Unknown
Clinical update -
SB11 (Proposed ranibizumab biosimilar) — Phase 3
Clinical update -
Rebamipide 2% ophthalmic solution — Approved
Clinical update -
Pemetrexed — Phase 2
Clinical update -
Lidocaine IV — Unknown
Clinical update
Trial registry
-
CTIS ↗ -
CTIS ↗ - 2025-520599-24-00CTIS ↗
Byooviz 10 mg/ml solution for injection
Neovascular Age-Related Macular Degeneration (AMD), Macular Oedema Secondary to Retinal Vein Occlusion (RVO), Myopic Choroidal Neovascularization (mCNV)
-
CTIS ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗